Drugs / N-acetyl D-mannosamine
N-acetyl D-mannosamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02639260 | Jul 2016 → Jun 2018 | kidney disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-acetyl D-mannosamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02639260 ↗ |
| Known as | ManNAc | “ManNAc (N-acetyl D-mannosamine) is an uncharged monosaccharide that is the biologic precursor of N-acetyl neuraminic acid (Neu5Ac, sialic acid).” NCT02639260 ↗ |
| Known as | N-acetylmannosamine | “oral administration of the metabolic SA precursor, N-acetylmannosamine (ManNAc) restored sialylation and reduced proteinuria, suggesting therapeutic potential.” PMID 41630898 ↗ Dec 2025 |
| Action | Restore | “N-acetylmannosamine (ManNAc) restored sialylation and reduced proteinuria” PMID 41630898 ↗ Dec 2025 |
| Modality | Other / unclassified | “ManNAc (N-acetyl D-mannosamine) is an uncharged monosaccharide” NCT02639260 ↗ |
| Route | Oral | “oral ManNAc” NCT02639260 ↗ |